Puma Biotech Investors Ink $54M Deal Over Drug Statements
Investors alleging that Puma Biotechnology Inc. misstated the effectiveness of a breast cancer treatment, causing the biopharmaceutical company's share price to drop, asked a California federal judge Monday to preliminarily approve...To view the full article, register now.
Already a subscriber? Click here to view full article